Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Detalles Bibliográficos
Autores principales: Ozkaynak, M. Fevzi, Gilman, Andrew L., London, Wendy B., Naranjo, Arlene, Diccianni, Mitchell B., Tenney, Sheena C., Smith, Malcolm, Messer, Karen S., Seeger, Robert, Reynolds, C. Patrick, Smith, L. Mary, Shulkin, Barry L., Parisi, Marguerite, Maris, John M., Park, Julie R., Sondel, Paul M., Yu, Alice L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055015/
https://www.ncbi.nlm.nih.gov/pubmed/30046297
http://dx.doi.org/10.3389/fimmu.2018.01641
Descripción
Sumario:

Ejemplares similares